193 related articles for article (PubMed ID: 36758171)
1. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.
Tang X; Xing S; Ma M; Xu Z; Guan Q; Chen Y; Feng F; Liu W; Chen T; Chen Y; Sun H
J Med Chem; 2023 Feb; 66(4):2282-2307. PubMed ID: 36758171
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
3. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
Lee BD; Dawson VL; Dawson TM
Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
[TBL] [Abstract][Full Text] [Related]
4. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications.
Andersen MA; Sotty F; Jensen PH; Badolo L; Jeggo R; Smith GP; Christensen KV
eNeuro; 2019; 6(6):. PubMed ID: 31685675
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.
Cao R; Chen C; Wen J; Zhao W; Zhang C; Sun L; Yuan L; Wu C; Shan L; Xi M; Sun H
Bioorg Chem; 2023 Dec; 141():106906. PubMed ID: 37837728
[TBL] [Abstract][Full Text] [Related]
7. Recent Update on the Development of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors: A Promising Target for the Treatment of Parkinson's Disease.
Patel A; Patel S; Mehta M; Patel Y; Langaliya D; Bhalodiya S; Bambharoliya T
Med Chem; 2022; 18(7):757-771. PubMed ID: 35168510
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
Wojewska DN; Kortholt A
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present).
Ding X; Ren F
Expert Opin Ther Pat; 2020 Apr; 30(4):275-286. PubMed ID: 32049564
[No Abstract] [Full Text] [Related]
10. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
11. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.
Estrada AA; Sweeney ZK
J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084
[TBL] [Abstract][Full Text] [Related]
12. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.
Baidya AT; Deshwal S; Das B; Mathew AT; Devi B; Sandhir R; Kumar R
Bioorg Chem; 2024 Feb; 143():106972. PubMed ID: 37995640
[TBL] [Abstract][Full Text] [Related]
13. Targeting LRRK2 in Parkinson's disease: an update on recent developments.
Chan SL; Tan EK
Expert Opin Ther Targets; 2017 Jun; 21(6):601-610. PubMed ID: 28443359
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 in Parkinson disease: challenges of clinical trials.
Tolosa E; Vila M; Klein C; Rascol O
Nat Rev Neurol; 2020 Feb; 16(2):97-107. PubMed ID: 31980808
[TBL] [Abstract][Full Text] [Related]
15. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
Azeggagh S; Berwick DC
Br J Pharmacol; 2022 Apr; 179(8):1478-1495. PubMed ID: 34050929
[TBL] [Abstract][Full Text] [Related]
16. Recent Developments in LRRK2-Targeted Therapy for Parkinson's Disease.
Zhao Y; Dzamko N
Drugs; 2019 Jul; 79(10):1037-1051. PubMed ID: 31161537
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
18. Small-Molecule Inhibitors of LRRK2.
Hatcher JM; Choi HG; Alessi DR; Gray NS
Adv Neurobiol; 2017; 14():241-264. PubMed ID: 28353288
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
[TBL] [Abstract][Full Text] [Related]
20. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
Chen J; Chen Y; Pu J
Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
